A clot-busting drug recently approved to treat acute ischemic strokes (AIS) that can be delivered quickly works as well as a ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

After a year of controversy and complaints, Sen. Elizabeth Warren is asking a federal watchdog to investigate GSK over its ...

ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...

Eli Lilly CEO Dave Ricks made $114 million last year, according to a new proxy statement, a rare instance of a health ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

The drug shortages are the result of manufacturing problems, increased demand, and other issues.View on euronews ...

Prevalence rates of what GSK calls "deviant" sexual behaviours caused by the drugs are unknown and tend to be under-reported ...

The founders of Bugworks Research are attempting to bring to market a new class of antibiotics--a first in almost half a ...

One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...

Felix sat down with Imperial graduate and life sciences consultant Sayak Bhattacharya to discuss the state of the ...